ArriVent
PublicArriVent is now publicly traded
The data on this page reflects ArriVent's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 25, 2024
Last Round
Follow-on Offering
Jul 3, 2025
Total Funding Raised
$555M
Company Overview
ArriVent Biopharma (NAS: AVBP) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to meet the unmet medical needs of cancer patients.
Sector
Biotech
AI Layer
Non-AI
Keywords
ArriVent Comparables
Compare ArriVent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ApolloBio Corp. | 43% | |
| Arrivo BioVentures | 40% |
ArriVent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jul 3, 2025 | ||||
| IPO | Jan 25, 2024 | ||||
| Series B | Mar 27, 2023 | ||||
| Series A | Jun 30, 2021 |
ArriVent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series B |
| Jefferies | IPO |
| JonesTrading | Follow-on Offering |
| Shanghai Healthcare Capital | Series B |
| Guggenheim Securities | Follow-on Offering |
| Hillhouse Investment | Series A |
| H.C. Wainwright & Co. | Follow-on Offering |
ArriVent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access